The researchers now plan to apply the linked-read technology to additional cancer samples as well as other disease cohorts with suspected structural variants.
The Intermountain spinout will use the Series A financing to commercialize and expand its precision cancer care offering, including the TheraMap solution.
Philips has teamed with Illumina and Intermountain Healthcare's Navican on informatics for precision medicine and signed a genome analytics deal with Memorial Sloan Kettering Cancer Center.
The leaner panel, an option for patients who lack sufficient tissue samples for more comprehensive profiling, has helped reduce test rejection rates by 80 percent.
Sync for Genes seeks to leverage HL7 FHIR infrastructure to communicate information from clinical genomic labs in a format for universal use across medicine.
Navican is hoping to bring some of the genomic testing and related services Intermountain has been offering for three years to the broader cancer community.
Through Navican, patients at Intermountain can get tested on an internally developed NGS platform that gauges a range of actionable genes implicated in cancer.
The agreement with Taiwan's Prisma Biotech is the second distribution deal in Asia for Intermountain Precision Genomics' ICG100 tumor sequencing test.
Non-randomized studies have downsides, but researchers say they are a way to gather incremental evidence on precision oncology approaches without denying patients access.
The test, called ICG100, is based on a set of 100 genes that are analyzed for mutations that can help guide a cancer patient's treatment regimen.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.